Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00200967 · ClinicalTrials.gov registry record · Phase 3

Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)

A Phase 3 study, sponsored by Milton S. Hershey Medical Center.

Completed
Registry status
Phase 3
Development phase
87
Enrollment target

NCT00200967: Completed Phase 3 study, sponsored by Milton S. Hershey Medical Center.

NCT00200967 is a Phase 3 study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 87 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00200967, a Phase 3 study, has completed, sponsored by Milton S. Hershey Medical Center.

COMPLETED
Registry status
Phase 3
Development phase
87 participants
Enrollment target

Study Summary

The purpose of this trial is to determine whether regularly scheduled use of an inhaled long-acting beta agonist (salmeterol) in the setting of concomitant use of inhaled corticosteroids (beclomethasone hydroflouroalkane (HFA) inhaler) will have a detrimental effect on asthma control in people who bear the B16-Arg/Arg genotype of the beta-2 adrenergic receptor gene, as compared to people with asthma of similar severity who bear the B16-Gly/Gly genotype.

Primary Outcome

Change between placebo salmeterol and active salmeterol for AM PEF rate

Interventions

  • DRUG salmeterol
  • DRUG beclomethasone HFA

Trial Details

FieldValue
Enrollment Target 87 participants
Start Date 2004-12
Est. Completion 2008-02
Phase Phase 3
Milton S. Hershey Medical Center

396 total trials

What the finished NCT00200967 record still lists

NCT00200967 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% lower).

The record links to 0 conditions, and to 2 interventions - of which salmeterol is the first listed.

NCT00200967 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00200967 about?

NCT00200967 is a clinical study titled "Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)". The purpose of this trial is to determine whether regularly scheduled use of an inhaled long-acting beta agonist (salmeterol) in the setting of concomitant use of inhaled corticosteroids (beclomethasone hydroflouroalkane (HFA) inhaler) will have a detrimental effect on asthma control in people who b...

What is the current status of trial NCT00200967?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 87 participants. The study started on 2004-12. Estimated completion is 2008-02.

What interventions are being tested in trial NCT00200967?

The interventions under investigation include: salmeterol (DRUG), beclomethasone HFA (DRUG).

Who is sponsoring clinical trial NCT00200967?

This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00200967's enrollment target sits among peer trials

87 1742nd of 2000 higher than 256 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03292601 · 87 participants · NA

    Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)

  • NCT04291105 · 87 participants · Phase 2

    Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

  • NCT04565795 · 87 participants · NA

    Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy

  • NCT05607004 · 87 participants · Phase 2

    (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00200967, the US trial registry maintained by the National Library of Medicine. NCT00200967 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.